Asia Pacific Academy of Science Pte. Ltd. (APACSCI) specializes in international journal publishing. APACSCI adopts the open access publishing model and provides an important communication bridge for academic groups whose interest fields include engineering, technology, medicine, computer, mathematics, agriculture and forestry, and environment.
Urinary tract infection and its impact on sexual health
Vol 3, Issue 2, 2022
VIEWS - 4365 (Abstract)
Download PDF
Abstract
A sexual dysfunction and lower urinary tract symptoms have been a hot issue in recent years for scientists to study. There have been several clinical epidemiologic studies conducted in order to examine the connections between these two seemingly unrelated areas of urology research. In this review, an attempt is made to address these two sectors, their influence on patients’ quality of life, shared pathophysiological processes, and therapeutic features. Many urological patients suffer from both conditions, which are widespread in the general community. Phosphodiesterase type 5 inhibitors, the generally accepted combo therapy in this situation, sparked interest in finding alternative therapeutic choices.
Keywords
References
1. Schappert SM, Rechtsteiner EA. Ambulatory medical care utilization estimates for 2007. Vital Health Statistics. Series 13 2007; 169: 1–38.
2. SIGN. Management of suspected bacterial urinary tract infection in adults. UK: Scottish Intercollegiate Guidelines Network; 2012.
3. Zielske JV, Brook RH, Goldberg GA. Conceptualization and measurement of physiologic health for adults. Urinary tract infection. Santa Monica, USA: The Rand Corporation; 1981.
4. Taur Y, Smith MA. Adherence to the Infectious Diseases Society of America guidelines in the treatment of uncomplicated urinary tract infection. Clinic Infectious Diseases 2007; 44: 769–774.
5. Foxman B, Barlow R, D’Arcy H, et al. Urinary tract infection: Self-reported incidence and associated costs. Annual of Epidemiology 2000; 10: 509–515.
6. Kupelian V, Wei J, O’Leary MP, et al. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: The Boston area community health (BACH) survey. Archives of Internal Medicine 2006; 166(21): 2381–2387.
7. Agarwal A, Eryuzlu LN, Cartwright R, et al. What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women. European Urology 2014; 65(6): 1211–1217.
8. De Ridder D, Roumeguère T, Kaufman L. Urgency and other lower urinary tract symptoms in men aged >/= 40 years: A Belgian epidemiological survey using the ICIQ-MLUTS questionnaire. International Journal of Clinical Practice 2015; 69(3): 358–365.
9. Taub DA, Wei J. The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States. Current Urology Reports 2006; 7(4): 272–281.
10. Chapple C, Abrams P. Lower Urinary Tract Symptoms (LUTS): An international consultation on male LUTS. Canada: Societe Internationale d’Urologie (SIU); 2013.
11. Chapple CR, Wein AJ, Abrams P, et al. Lower urinary tract symptoms revisited: A broader clinical perspective. European Urology 2008; 54(3): 563–569.
12. Gacci M, Corona G, Vignozzi L, et al. Metabolic syndrome and benign prostatic enlargement: A systematic review and meta-analysis. BJU International 2015; 115: 24.
13. Ficarra V, Rossanese M, Zazzara M, et al. The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy. Current Urology Reports 2014; 15: 463.
14. He Q, Wang Z, Liu G, et al. Metabolic syndrome, inflammation and lower urinary tract symptoms: Possible translational links. Prostate Cancer and Prostatic Diseases 2016; 19: 7.
15. Drake MJ. Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013. Neurourology and Urodynamics 2014; 33: 622.
16. Novara G, Galfano A, Gardi M, et al. Critical review of guidelines for BPH diagnosis and treatment strategy. European Urology Supplements 2006; 5(4): 418.
17. McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. The Journal of Urology 2011; 185(5): 1793.
18. Bosch J, Abrams P, Cotterill N, et al. Lower urinary tract symptoms in men: Etiology, patient assessment and predicting outcome from therapy. In: Chapple C, Abrams P (editors). Male lower urinary tract symptoms (LUTS). An International Consultation on Male LUTS; 2012 Sep 30–Oct 4; Fukuoka, Japan. Montréal, Canada: Société Internationale d'Urologie (SIU); 2013. p. 37–133.
19. Martin RM, Vatten L, Gunnell D, et al. Lower urinary tract symptoms and risk of prostate cancer: The HUNT 2 cohort, Norway. International Journal of Cancer 2008; 123: 1924.
20. Young JM, Muscatello DJ, Ward JE, et al. Are men with lower urinary tract symptoms at increased risk of prostate cancer? A systematic review and critique of the available evidence. BJU International 2000; 85: 1037.
21. Donovan JL, Peters TJ, Abrams P, et al. Scoring the short form ICS male SF questionnaire. International continence society. The Journal of Urology 2000; 164: 1948.
22. Epstein RS, Deverka PA, Chute CG, et al. Validation of a new quality of life questionnaire for benign prostatic hyperplasia. Journal of Clinical Epidemiology 1992; 45(12): 1431–1445.
23. Homma Y, Yoshida M, Seki N, et al. Symptom assessment tool for overactive bladder syndrome—Overactive bladder symptom score. Urology 2006; 68(2): 318.
24. Schou J, Poulsen AL, Nordling J. The value of a new symptom score (DAN-PSS) in diagnosing uro-dynamic infravesical obstruction in BPH. Scandinavian Journal of Urology and Nephrology 1993; 27(4): 489–492.
25. Homma Y, Yoshida M, Yamanishi T, et al. Core lower urinary tract symptom score (CLSS) questionnaire: A reliable tool in the overall assessment of lower urinary tract symptoms. International Journal of Urology 2008; 15(9): 816–820.
26. D’Silva KA, Dahm P, Wong CL. Does this man with lower urinary tract symptoms have bladder outlet obstruction? The rational clinical examination: A systematic review. JAMA 2014; 312(5): 535–542.
27. Bryan NP, Chapple CR. Frequency volume charts in the assessment and evaluation of treatment: How should we use them? European Urology 2004; 46(5): 636–640.
28. Salonia A, Castagna G, Saccà A, et al. Is erectile dysfunction a reliable proxy of general male health status? The case for the international index of erectile function-erectile function domain. The Journal of Sexual Medicine 2012; 9(10): 2708–2715.
29. Fisher WA, Eardley I, McCabe M, et al. Erectile dysfunction (ED) is a shared sexual concern of couples I: Couple conceptions of ED. The Journal of Sexual Medicine 2009; 6(10): 2746–2760.
30. Dong J, Zhang Y, Qin L. Erectile dysfunction and risk of cardiovascular disease: Meta-analysis of prospective cohort studies. Journal of the American College of Cardiology 2011; 58: 1378–1385.
31. Gandaglia G, Briganti A, Jackson G, et al. A systematic review of the association between erectile dysfunction and cardiovascular disease. European Urology 2014; 65(5): 968–978.
32. Gupta BP, Murad MH, Clifton MM, et al. The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: A systematic review and meta-analysis. Archives of Internal Medicine 2011; 171(20): 1797–1803.
33. Braun M, Wassmer G, Klotz T, et al. Epidemiology of erectile dysfunction: Results of the ‘cologne
34. male survey’. International Journal of Impotence Research 2000; 12: 305–311.
35. Johannes CB, Araujo AB, Feldman HA, et al. Incidence of erectile dysfunction in men 40 to 69 years old: Longitudinal results from the Massachusetts male aging study. The Journal of Urology 2000; 163(2): 460–463.
36. Schouten BW, Bosch JL, Bernsen RM, et al. Incidence rates of erectile dysfunction in the Dutch general population. Effects of definition, clinical relevance and duration of follow-up in the Krimpen study. International Journal of Impotence Research 2005; 17(1): 58–62.
37. Colson MH, Cuzin B, Faix A, et al. Current epidemiology of erectile dysfunction, an update. Sexologies 2018; 27: 7–13.
38. Colson MH, Cuzin B, Faix A, et al. Much more than prescribing a pill: Stepwise approach to erectile dysfunction management. Sexologies 2018; 27: 18–22
39. Capogrosso P, Colicchia M, Ventimiglia E, et al. One patient out of four with newly diagnosed erectile dysfunction is a young man—Worrisome picture from the everyday clinical practice. The Journal of Sexual Medicine 2013; 10(7): 1833–1841.
40. Buvat J, Maggi M, Gooren L, et al. Endocrine aspects of male sexual dysfunctions. The Journal of Sexual Medicine 2010; 7(4 Pt 2): 1627–1656.
41. Jackson G, Montorsi P, Adams MA, et al. Cardiovascular aspects of sexual medicine. The Journal of Sexual Medicine 2010; 7(4 Pt 2): 1608–1626.
42. Akpinar E, Uysal Y, Bozdemir N, et al. Prevalence of erectile dysfunction among Turkish heterosexual men. Scientific Journal of Medical Science (SJMS) 2013; 2(11): 225–231
43. Tan JK, Hong CY, Png DJ, et al. Erectile dysfunction in Singapore: Prevalence and its associated factors—A population-based study. Singapore Medical Journal 2003; 44(1): 20–26.
44. Binmoammar TA, Hassounah S, Alsaad S, et al. The impact of poor glycaemic control on the prevalence of erectile dysfunction in men with type 2 diabetes mellitus: A systematic review. Journal of the Royal Society of Medicine Open 2016; 7(3): 1–10.
45. Glina S, Sharlip ID, Hellstrom WJ. Modifying risk factors to prevent and treat erectile dysfunction. The Journal of Sexual 2013; 10(1): 115–119.
46. Vlachopoulos C, Jackson G, Stefanadis C, et al. Erectile dysfunction in the cardiovascular patient. European Heart Journal 2013; 34(27): 2034–2046.
47. Seftel AD, de la Rosette J, Birt J, et al. Coexisting lower urinary tract symptoms and erectile dysfunction: A systematic review of epidemiological data. International Journal of Clinical Practice 2013; 67(1): 32–45.
48. Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: The multinational survey of the aging male (MSAM-7). European Urology 2003; 44(6): 637–649.
49. Molina-Leyva A, Jiménez-Moleón JJ, Naranjo- Sintes R, et al. Sexual dysfunction in psoriasis: A systematic review. Journal of the European Academy of Dermatology and Venereology 2015; 29(4): 649–655.
50. Fan D, Liu L, Ding N, et al. Male sexual dysfunction and ankylosing spondylitis: A systematic review and meta-analysis. The Journal of Rheumatology 2015; 42(2): 252–257.
51. Duman DG, Biçakci E, Çelikel ÇA, et al. Nonalcoholic fatty liver disease is associated with erectile dysfunction: A prospective pilot study. The Journal of Sexual Medicine 2016; 13(3): 383–388.
52. Salonia A, Burnett AL, Graefen M, et al. Prevention and management of postprostatectomy sexual dysfunctions part 2: Recovery and preservation of erectile function, sexual desire, and orgasmic function. European Urology 2012; 62(2): 273–286.
53. Salonia A, Burnett AL, Graefen M, et al. Prevention and management of postprostatectomy sexual dysfunctions. Part 1: Choosing the right patient at the right time for the right surgery. European Urology 2012; 62(2): 273–286.
54. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. The New England Journal of Medicine 2008; 358(12): 1250–1261.
55. Schauer I, Keller E, Müller A, et al. Have rates of erectile dysfunction improved within the past 17 years after radical prostatectomy? A systematic analysis of the control arms of prospective randomized trials on penile rehabilitation. Andrology 2015; 3(4): 661–665.
56. Ficarra V, Novara G, Ahlering TE, et al. Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. European Urology 2012; 62(3): 418–430.
57. Stolzenburg JU, Graefen M, Kriegel C, et al. Effect of surgical approach on erectile function recovery following bilateral nerve-sparing radical prostatectomy: An evaluation utilizing data from a randomized, double-blind, double-dummy multicenter trial of tadalafil vs placebo. BJU International 2015; 116(2): 241–251.
58. World Health Organization (ICD-10). International statistical classification of diseases and related health problems. Geneva: WHO; 1992.
59. Graham CA. The DSM diagnostic criteria for female orgasmic disorder. Archives of Sexual Behavior 2010; 39(2): 256–270.
60. Hatzichristou DG, Hatzimouratidis K, Apostolidis A, et al. Hemodynamic characterization of a functional erection: Arterial and corporeal veno-occlusive function in patients with a positive intracavernosal injection test. European Urology 1999; 36(1): 60–67.
61. Sikka SC, Hellstrom WJ, Brock G, et al. Standardization of vascular assessment of erectile dysfunction: Standard operating procedures for duplex ultrasound. The Journal of Sexual Medicine 2013; 10(1): 120–129.
62. Glina S, Ghanem H. SOP: Corpus cavernosum assessment (cavernosography/cavernosometry). The Journal of Sexual Medicine 2013; 10(1): 111–114.
63. Hatzichristou D, Rosen RC, Derogatis LR, et al. Recommendations for the clinical evaluation of men and women with sexual dysfunction. The Journal of Sexual Medicine 2010; 7(1 Pt 2): 337–348.
64. Kirby M, Chapple C, Jackson G, et al. Erectile dysfunction and lower urinary tract symptoms: A consensus on the importance of co-diagnosis. International Journal of Clinical Practice 2013; 67(7): 606–618.
65. Orabi H, Albersen M, Lue T. Association of lower urinary tract symptoms and erectile dysfunction: Pathophysiological aspects and implications for clinical management. International Journal of Impotence Research 2011; 23: 99–108.
66. Köhler TS, McVary KT. The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors. European Urology 2009; 55: 38–48.
67. Gacci M, Eardley I, Giuliano F, et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. European Urology 2011; 60: 809–825.
68. Rantell A, Apostolidis A, Anding R, et al. How does lower urinary tract dysfunction affect sexual function in men and women? ICI-RS 2015-Part 1. Neurourology and Urodynamics 2017; 36: 949–952.
69. Giona S, Ganguly I, Muir G. Urologists’ attitudes to sexual complications of LUTS/BPH treatments. World of Journal Urology 2018; 36: 1449–1453.
70. Gacci M, Corona G, Salvi M, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. European Urology 2012; 61(5): 994–1003.
71. van Dijk MM, de la Rosette JJ, Michel MC. Effects of alpha (1)-adrenoceptor antagonists on male sexual function. Drugs 2006; 66: 287–301.
72. Roehrborn CG, Siami P, Barkin J, et al. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the combat study. European Urology 2009; 55: 461–471.
73. Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434–441.
74. Roehrborn CG, Siami P, Barkin J, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the combat study. The Journal of Urology 2008; 179: 616–621.
75. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. The New England Journal of Medicine 2003; 349: 2387–2398.
76. Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the combat study. European Urology 2010; 57: 123–131.
77. Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5 alpha-reductase inhibitors for the enlarged prostate. Clinical Therapeutics 2007; 29(1): 17–25.
78. Madersbacher S, Marberger M. Is transurethral resection of the prostate still justified? BJU International 1999; 83(3): 227–237.
79. McConnell JD, Barry MJ, Bruskewitz RC. Benign prostatic hyperplasia: Diagnosis and treatment. United States: Health and Human Services; 1994. p. 1–17.
80. Emberton M, Neal DE, Black N, et al. The effect of prostatectomy on symptom severity and quality of life. British Journal of Urology 1996; 77: 233–247.
81. Horasanli K, Silay MS, Altay B, et al. Photoselective potassium titanyl phosphate (KTP) laser vaporization versus transurethral resection of the prostate for prostates larger than 70 ml: A short-term prospective randomized trial. Urology 2008; 71: 247–251.
82. Alivizatos G, Skolarikos A, Chalikopoulos D, et al. Transurethral photoselective vaporization versus transvesical open enucleation for prostatic adenomas >80 ml: 12-mo results of a randomized prospective study. European Urology 2008; 54: 427–437.
83. Bouchier-Hayes DM, Anderson P, Van Appledorn S, et al. KTP laser versus transurethral resection: Early results of a randomized trial. Journal of Endourology 2006; 20: 580–585.
84. Naspro R, Suardi N, Salonia A, et al. Holmium laser enucleation of the prostate versus open prostatectomy for prostates >70 g: 24-month follow-up. European Urology 2006; 50: 563–568.
85. Briganti A, Naspro R, Gallina A, et al. Impact on sexual function of holmium laser enucleation versus transurethral resection of the prostate: Results of a prospective, 2-center, randomized trial. The Journal of Urology 2006; 175: 1817–1821.
86. Kim M, Song SH, Ku JH, et al. Pilot study of the clinical efficacy of ejaculatory hood sparing technique for ejaculation preservation in holmium laser enucleation of the prostate. International Journal of Impotence Research 2014; 27: 20–24.
87. Bruskewitz R, Issa MM, Roehrborn CG, et al. A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. The Journal of Urology 1998; 159: 1588–1593.
88. Hill B, Belville W, Bruskewitz R, et al. Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicentre clinical trial. The Journal of Urology 2004; 171: 2336–2340.
89. Cimentepe E, Unsal A, Saglam R. Randomized clinical trial comparing transurethral needle ablation with transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: Results at 18 months. Journal of Endourology/Endourological Society 2003; 17: 103.
90. Woo HH, Chin PT, McNicholas TA, et al. Safety and feasibility of the prostatic urethral lift: A novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU International 2011; 108: 82–88.
91. Filippi S, Morelli A, Sandner P, et al. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007; 148(3): 1019–1029.
92. Fibbi B, Morelli A, Vignozzi L, et al. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. The Journal of Sexual Medicine 2010; 7(1 Pt 1): 59–69.
93. Morelli A, Filippi S, Comeglio P, et al. Acute vardenal administration improves bladder oxygenation in spontaneously hypertensive rats. The Journal of Sexual Medicine 2010; 7(1 Pt 1): 107–120.
94. Morelli A, Sarchielli E, Comeglio P, et al. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. The Journal of Sexual Medicine 2011; 8(10): 2746–2760.
95. McVary KT, Roehrborn CG, Kaminetsky JC, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. The Journal of Urology 2007; 177(4): 1401–1407.
96. Miyazato M, Tohyama K, Touyama M, et al. Effect of continuous positive airway pressure on nocturnal urine production in patients with obstructive sleep apnea syndrome. Neurourology and Urodynamics 2017; 36: 376–379.
Refbacks
- There are currently no refbacks.
Copyright (c) 2022 Ramaiyan Velmurugan, S. Sharmili
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
.png)
Prof. Wei-Yen Hsu
National Chung Cheng University, Taiwan
